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Abstract. 
 
Protein tyrosine phosphatase PTP-SL retains 
mitogen-activated protein (MAP) kinases in the cyto-
plasm in an inactive form by association through a ki-
nase interaction motif (KIM) and tyrosine dephos-
phorylation. The related tyrosine phosphatases PTP-SL 
and STEP were phosphorylated by the cAMP-depen-
dent protein kinase A (PKA). The PKA phosphoryla-
 
tion site on PTP-SL was identiﬁed as the Ser
 
231
 
 residue, 
located within the KIM. Upon phosphorylation of 
Ser
 
231
 
, PTP-SL binding and tyrosine dephosphorylation 
of the MAP kinases extracellular signal–regulated ki-
nase (ERK)1/2 and p38
 
a
 
 were impaired. Furthermore, 
treatment of COS-7 cells with PKA activators, or over-
expression of the C
 
a
 
 catalytic subunit of PKA, inhib-
ited the cytoplasmic retention of ERK2 and p38
 
a
 
 by 
wild-type PTP-SL, but not by a PTP-SL S231A mutant. 
These ﬁndings support the existence of a novel mecha-
nism by which PKA may regulate the activation and 
translocation to the nucleus of MAP kinases.
Key words: MAP kinases • PKA • PTP-SL • tyrosine 
phosphatases • signal transduction
 
T
 
HE
 
 mammalian mitogen-activated protein (MAP)
 
1
 
kinase pathways are signaling cascades differen-
tially activated by growth factors, mitogens, hor-
mones, as well as by stress and inflammation, which con-
tribute to the control of cell growth, differentiation, and
survival (Cobb and Goldsmith, 1995; Kyriakis and Avruch,
1996). Each pathway behaves as a multimolecular complex
of receptors and regulatory and adapter proteins, which
are functionally assembled around a modular core of three
kinases (Whitmarsh and Davis, 1998; Schaeffer and We-
ber, 1999). A major mechanism of internal regulation and
signal amplification of these cascades is the sequential
phosphorylation and activation of the kinases within each
three-kinase module, leading to the activation in the cyto-
plasm of the effector kinases extracellular signal–regu-
lated kinase (ERK)1/2, c-Jun NH
 
2
 
-terminal kinase (JNK),
or p38, and their translocation to the nucleus, where phos-
phorylation of transcription factors takes place (Karin,
1995; Treisman, 1996). In addition, the crosstalk between
distinct MAP kinases cascades as well as with protein ki-
nases from other pathways, such as protein kinase A or C
(PKA or PKC, respectively), cooperates in the integration
of the signals delivered through the MAP kinases (Burger-
ing and Bos, 1995; Robinson and Cobb, 1997). The partici-
pation of the cAMP-dependent protein kinase, PKA, in
the differential modulation of MAP kinase pathways has
been documented. For instance, in T lymphocytes, PKA
mediates the inhibition of the JNK but not of the ERK1/2
pathway (Hsueh and Lai, 1995), whereas in Rat1 fibro-
blasts, adipocytes, and muscle cells, PKA inhibits ERK1/2
by interfering with the activation of Raf-1 by Ras (Cook
and McCormick, 1993; Graves et al., 1993; Sevetson et al.,
1993; Wu et al., 1993). Conversely, PKA cooperates in the
sustained activation of ERK1/2 in pheochromocytoma
PC12 cells, in a process that involves the activation of the
Rap1/B-Raf pathway (Frödin et al., 1994; Vossler et al.,
1997).
The protein tyrosine phosphatases PTP-SL, STEP, and
HePTP have emerged as major regulators of MAP kinase
functions on the basis of their association with ERK1/2
and p38 through a 16–amino acid kinase interaction motif
(KIM), located in their cytosolic noncatalytic regions
(Pulido et al., 1998; Oh-hora et al., 1999; Saxena et al.,
1999a; Zúñiga et al., 1999). PTP-SL is encoded by a single
gene, although different transcripts have been described
that generate distinct transmembrane and nontransmem-
brane isoforms, which are excluded from the nucleus and
whose expression is developmentally regulated in the
brain (Hendriks et al., 1995; Ogata et al., 1995; Sharma
and Lombroso, 1995; Shiozuka et al., 1995). Binding of
ERK1/2 to the KIM of PTP-SL blocks the nuclear translo-
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cation of these MAP kinases, and favors their dephosphor-
ylation and inactivation by the phosphatase in the cyto-
plasm (Zúñiga et al., 1999). Essential residues within the
KIM of PTP-SL for the recognition of ERK1/2 include
those within a PKA consensus phosphorylation sequence,
raising the possibility that PKA could regulate the associa-
tion of PTP-SL with the MAP kinases by KIM phosphory-
lation. In this report, we have investigated the involvement
of PKA in the regulation of the association of PTP-SL
with ERK1/2 and p38
 
a
 
. We have found that phosphoryla-
tion of the KIM of PTP-SL by PKA is a major regulatory
mechanism of the activities of these MAP kinases and
their translocation to the nucleus.
 
Materials and Methods
 
Plasmids, Antibodies, and Reagents
 
PTP-SL, STEP, and ERK2 cDNA constructs have been previously de-
scribed (Pulido et al., 1998; Zúñiga et al., 1999). pC
 
a
 
EV (cPKA
 
a
 
, mouse
sequence; Uhler and McKnight, 1987) was provided by G.S. McKnight
(University of Washington, Seattle, WA). pECE-HA-p38MAPK (p38
 
a
 
,
mouse sequence; Brunet and Pouysségur, 1996) was provided by J.
Pouysségur (Centre de Biochimie-CNRS, Nice, France). pRK5-GST-
PTP-SL mammalian expression vectors were made by PCR with a primer
containing a Kozak sequence followed by a start codon and the 
 
S
 
.
 
 Ja-
panicum
 
 glutathione-S-transferase (GST) sequence. Antibodies and
reagents were used as described (Pulido et al., 1998; Zúñiga et al., 1999).
Rabbit polyclonal anti-p38
 
a
 
 (C-20) was purchased from Santa Cruz Bio-
technology Inc. Dibutyryl-cAMP and okadaic acid (Boehringer Mann-
heim) were used at final concentrations of 2 mM and 1 
 
m
 
M, respectively.
Forskolin (ICN Pharmaceuticals Inc.) was used at a final concentration of
40 
 
m
 
M, in the continuous presence of 1 mM IBMX (Sigma Chemical Co.).
The PKA inhibitor H89 (Biomol) was used at a final concentration of 25
 
m
 
M. When used, IBMX and H89 were added to the cells 30 min before
stimulation. The bovine PKA catalytic subunit (cPKA) was purchased
from Promega Corp.
 
In Vitro Kinase and Phosphatase Assays
 
For PKA in vitro kinase assays, GST fusion proteins (1 
 
m
 
g) were incu-
bated at room temperature during 1 h with 0.5 U/
 
m
 
l of cPKA in the pres-
ence of 2 
 
m
 
Ci of 
 
g
 
-[
 
32
 
P]ATP, 10 
 
m
 
M ATP, and 8 mM MgCl
 
2
 
 (20 
 
m
 
l final
volume). The reactions were stopped by adding SDS sample buffer and
boiling, followed by SDS-PAGE and autoradiography. For in vitro associ-
ation assays (see Fig. 2 A), GST fusion proteins were phosphorylated with
cPKA as above, in the presence of 200 
 
m
 
M cold ATP, and then mixed with
cell lysates and precipitated with glutathione-Sepharose, followed by im-
munoblotting. In vitro phosphatase assays were performed in 25 mM
Hepes, pH 7.3, 5 mM EDTA, and 10 mM DTT (40 
 
m
 
l final volume), at
37
 
8
 
C, during the indicated times, as described in Zúñiga et al. (1999).
 
Cell Culture, Transfections, Precipitation with GST 
Fusion Proteins, Immunoprecipitation,
and Immunoblotting
 
Rat fibroblast Rat-1, human embryonic kidney 293, and Simian COS-7
cell lines, were grown in DME containing high glucose supplemented with
5% (for COS-7 cells) or 10% heat-inactivated FCS. Cells were transfected
using the DEAE-dextran method (COS-7 cells) or the calcium phosphate
precipitation method (293 cells), and were harvested after 48–72 h of cul-
ture. In cells transfected with pC
 
a
 
EV, the expression of cPKA
 
a
 
 was in-
duced by incubation during the last 24 h of culture in the presence of 100
 
m
 
M ZnSO
 
4
 
. For 
 
32
 
P-labeling, transfected COS-7 cells were cultured for 4 h
with phosphate-free DME 2% FCS in the presence of [
 
32
 
P]inorganic phos-
phate (100 
 
m
 
Ci/ml), and then cells were treated with dibutyryl-cAMP or
forskolin plus IBMX during 1 h, or with okadaic acid during 30 min. HA-
ERK2 or HA-p38
 
a
 
 from transfected 293 cells were activated by cell treat-
ment with EGF (5 min, 50 ng/ml) or sorbitol (30 min, 0.5 M), respectively.
Cell lysis, precipitation with GST-fusion proteins, immunoprecipitation,
and immunoblotting were done as described (Pulido et al., 1998).
 
Immunofluorescence
 
COS-7 cells were processed for immunofluorescence as described (Zúñiga
et al., 1999). In brief, after transfection, cells were rinsed with IPBS buffer
(1.5 mM KH
 
2
 
PO
 
4
 
, 4.3 mM Na
 
2
 
HPO
 
4
 
, 137 mM NaCl, 2.7 mM KCl, 0.7 mM
CaCl
 
2
 
, and 0.5 mM MgCl
 
2
 
, pH 7.4), and then fixed with methanol. Sam-
ples were incubated in blocking solution (IPBS 3% BSA), followed by in-
cubation at 37
 
8
 
C for 90 min with the mixture of the anti-HA and anti–PTP-
SL primary antibodies. After washing with IPBS, cells were incubated for
1 h at room temperature with a mixture of the anti-rabbit fluorescein
isothiocyanate– and the anti-mouse tetramethylrhodamine B isothiocya-
nate–conjugated secondary antibodies, followed by washing with IPBS
and mounting.
 
Results
 
PKA Phosphorylates PTP-SL and STEP
 
PTP-SL and STEP tyrosine phosphatases contain a con-
served KIM in their cytosolic noncatalytic regions that me-
diates association with MAP kinases (Pulido et al., 1998).
Since a consensus phosphorylation sequence for PKA
occurs within the KIM (Arg
 
228
 
Arg
 
229
 
Gly
 
230
 
Ser
 
231
 
; amino
acid numbering is according to PTP-SL; Hendriks et al.,
1995), the phosphorylation of these two phosphatases by
PKA was tested. GST-PTP-SL or -STEP fusion proteins,
were incubated in vitro with cPKA in the presence of
 
g
 
-[
 
32
 
P]ATP, followed by SDS-PAGE and autoradiography.
As shown, a strong phosphorylation of the PTP-SL and
STEP fusion proteins was detected (Fig. 1 A, lanes 2–4),
whereas no phosphorylation took place with GST alone or
a GST fusion protein containing a nonrelated PTP (Fig. 1
A, lanes 1 and 5), indicating that PTP-SL and STEP are
Figure 1. Phosphorylation of PTP-SL and STEP by PKA. (A)
GST fusion proteins (1 mg) were phosphorylated in vitro by
cPKA in the presence of g-[32P]ATP as indicated. (B) COS-7 cells
were mock-transfected (pRK5 vector alone) or transfected with
the pRK5 PTP-SL wild type or S231A, as indicated, followed by
32P-labeling. Cells were left untreated (2) or were treated (1)
with dibutyryl-cAMP, forskolin, or okadaic acid, as described in
Materials and Methods. PTP-SL was precipitated from cell ly-
sates with anti–PTP-SL antibody. All samples (A and B) were re-
solved by 10% SDS-PAGE under reducing conditions, and fol-
lowed by autoradiography. 
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substrates of PKA. Substitution by alanine of the Ser
 
231
 
residue (S231A mutant), abolished the phosphorylation of
PTP-SL by cPKA (Fig. 1 A, lanes 8 and 10), demonstrat-
ing that this residue is the target of the kinase. Next, the in
vivo phosphorylation of PTP-SL upon PKA activation
conditions was investigated. Phosphorus 32 labeling was
carried out on COS-7 cells transfected with plasmids en-
coding transmembrane (PTP-SL 1-549) or nontransmem-
brane (PTP-SL 147-549) PTP-SL isoforms, followed by
treatment with PKA activators and immunoprecipitation
with anti–PTP-SL antibody. Incubation in the presence of
the cAMP analogous dibutyryl-cAMP or the adenylate cy-
clase activator forskolin increased the phosphorylation of
wild-type PTP-SL isoforms (Fig. 1 B, lanes 3, 4, and 8), but
not of the S231A mutants (Fig. 1 B, lanes 6 and 10). Inter-
estingly, the basal levels of phosphorylation were greatly
diminished in the S231A mutants (Fig. 1 B, lanes 5 and 9)
compared with the wild-type PTP-SL (Fig. 1 B, lanes 2 and
7), indicating that PKA phosphorylates this residue under
the normal cell growth conditions of COS-7 cells. Further-
more, cell treatment with the PP2A serine/threonine phos-
phatase inhibitor, okadaic acid (1 
 
m
 
M), induced the hyper-
phosphorylation of wild-type PTP-SL, but not of the
S231A mutant (Fig. 1 B, lanes 11–14). These results dem-
onstrate that the Ser
 
231
 
 residue of PTP-SL is a substrate of
PKA, and suggest a role for PP2A in the in vivo dephos-
phorylation of such a residue.
 
Phosphorylation of the KIM of PTP-SL by PKA Inhibits 
the Association and the Tyrosine Dephosphorylation of 
ERK1/2 and p38
 
a
 
Next, the effect of PTP-SL phosphorylation by PKA on its
association with MAP kinases was analyzed. GST-PTP-SL
fusion proteins were phosphorylated in vitro by cPKA as
above, in the presence of cold ATP, and the fusion pro-
teins were incubated with Rat-1 cell lysates and precipi-
tated with glutathione-Sepharose. Samples were resolved
by SDS-PAGE and the presence of the MAP kinases
ERK1/2 or p38
 
a
 
 was detected by immunoblot using
specific antibodies. Remarkably, the phosphorylation of
GST-PTP-SL wild type by cPKA abrogated its association
with both ERK1/2 and p38
 
a
 
 (Fig. 2 A, lane 2); however,
no changes were observed with the GST-PTP-SL S231A
mutant upon incubation with cPKA (Fig. 2 A, lanes 4 and
5). To test the effect of PTP-SL phosphorylation by PKA
on the association with the MAP kinases in vivo, GST-
PTP-SL fusion proteins were overexpressed in 293 cells
and precipitated in one-step with glutathione-Sepharose,
followed by immunoblot analysis, as above. Treatment of
cells with dibutyryl-cAMP or forskolin resulted in the lack
of coprecipitation of ERK1/2 or HA-p38
 
a
 
 with PTP-SL
(Fig. 2 B, lanes 2 and 3); however, in dibutyryl-cAMP–
treated cells that were preincubated with the PKA inhibi-
tor H89, normal levels of association with the kinases were
detected (Fig. 2 B, lane 4). Finally, the coprecipitation of
ERK1/2 and p38
 
a
 
 with the PTP-SL S231E mutant, which
mimics a phosphorylated Ser
 
231
 
 residue, was also tested.
As shown, these MAP kinases did not associate in 293
cells with overexpressed GST-PTP-SL S231E (Fig. 2 C,
lane 5), whereas association was efficiently detected with
the GST-PTP-SL wild type, the S231A mutant or the
C480S catalytically inactive mutant (Fig. 2 C, lanes 3, 4,
and 6). The functional consequences of the phosphoryla-
tion of the Ser
 
231
 
 residue of PTP-SL, on the dephosphory-
lation of ERK1/2 and p38
 
a
 
 by the phosphatase, were ana-
lyzed using the S231E PTP-SL mutant. GST-PTP-SL wild
type or S231E fusion proteins were mixed with pellets
containing activated HA-ERK2 or HA-p38
 
a
 
, and phos-
Figure 2. Effect of PTP-SL phosphorylation by PKA on the asso-
ciation with MAP kinases and their dephosphorylation. (A)
GST-PTP-SL 147-288 wild type or S231A fusion proteins (1.5 mg)
were left untreated (2) or were phosphorylated in vitro by cPKA
(1) in the presence of cold ATP, as indicated. Rat-1 cell lysates
(500 mg) were added, and the fusion proteins were precipitated
with glutathione-Sepharose. The kinases were detected by immu-
noblot analysis with anti–ERK1/2 (top) or anti–p38a (bottom)
antibodies. In lane 1, total lysate samples (20 mg) were loaded.
Arrowheads indicate the migration of the kinases. (B) 293 cells
were transfected with pRK5 GST-PTP-SL 147-549 (both panels);
in the bottom panel, cells were cotransfected with pECE-HA-
p38MAPK. After 48 h, cells were left untreated (2) or were
treated with dibutyryl-cAMP, dibutyryl-cAMP plus H89, or for-
skolin, as indicated. The GST-PTP-SL fusion proteins were pre-
cipitated from the cell lysates with glutathione-Sepharose, and
coprecipitated kinases were detected by immunoblot analysis
with anti–ERK1/2 (top) or anti–HA (bottom) antibodies. (C) 293
cells were transfected with pRK5 GST (lane 2) or the pRK5
GST-PTP-SL 147-549 wild type or mutants, as indicated, and fu-
sion proteins were precipitated as in B, followed by immunoblot
with anti-ERK1/2 or anti-p38a antibodies. In lane 1, total lysate
(20 mg) was loaded. All GST-PTP-SL proteins were equally ex-
pressed. (D) Tyrosine-phosphorylated HA-ERK2 or HA-p38a
were precipitated with the anti–HA 12CA5 mAb from activated
293 cells, transfected with pCDNA3-HA-ERK2 (lanes 1–5) or
pECE-HA-p38MAPK (lanes 6–10), and immune complexes were
subjected to in vitro phosphatase assays during the indicated
times (in minutes) in the presence of GST-PTP-SL 147-549 wild
type (lanes 2, 3, 7, and 8) or S231E (lanes 4, 5, 9, and 10) (1 mg).
In lanes 1 and 6, no fusion proteins were added, and samples
were kept on ice. Tyrosine phosphorylation was detected by im-
munoblot with the anti-phosphotyrosine 4G10 mAb (top panels).
Bottom panels show the equal presence of HA-ERK2 and HA-
p38a in all lanes, after stripping of the filters and reprobing with
the anti-HA 12CA5 mAb. Equal activities of GST-PTP-SL wild
type and S231E towards pNPP were measured (not shown). All
samples (A–D) were resolved by 10% SDS-PAGE under reduc-
ing conditions. 
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phatase assays were carried out, followed by SDS-PAGE
and immunoblot with the anti–phosphotyrosine 4G10
mAb. As shown, the tyrosine dephosphorylation of HA-
ERK2 and HA-p38
 
a
 
 by GST-PTP-SL S231E mutant was
impaired compared with that shown by GST-PTP-SL wild
type, whereas equal activities of both fusion proteins were
measured towards the nonspecific p-NPP substrate (Fig. 2
D and data not shown). These findings demonstrate that
phosphorylation of the Ser
 
231
 
 residue of PTP-SL by PKA
inhibits its association with ERK1/2 and p38
 
a
 
, and the sub-
sequent tyrosine dephosphorylation of these MAP kinases.
 
Nuclear Translocation of ERK2 and p38
 
a
 
, in the 
Presence of PTP-SL, Is Favored upon Activation
of PKA
 
PTP-SL retains ERK2 in the cytoplasm in a KIM-depen-
dent manner (Zúñiga et al., 1999). To study the effect of
phosphorylation of PTP-SL by PKA on its ability to retain
MAP kinases outside of the nucleus, immunofluorescence
analysis was performed on COS-7 cells cotransfected with
HA-ERK2 or HA-p38
 
a
 
,
 
 
 
and PTP-SL. Overexpression of
HA-ERK2 or HA-p38
 
a
 
 alone resulted in their accumula-
tion in the nucleus (see Fig. 4 A; and data not shown);
however, in the presence of PTP-SL, the nuclear accumu-
lation of these kinases was abolished, colocalizing with the
phosphatase outside of the nucleus (Figs. 3 and 4 A). In-
terestingly, neither the PTP activity nor the PTP domain
of PTP-SL itself was required to retain HA-ERK2 outside
of the nucleus, as observed by coexpression with PTP-SL
catalytically inactive mutants (C480S or R486M) or with
truncated PTP-SL forms lacking the PTP domain (PTP-SL
1-288) (Fig. 4 A). On the other hand, upon coexpression
with the PTP-SL S231E mutant, the cytoplasmic retention
of HA-ERK2 or HA-p38
 
a
 
 was significantly reduced, as
compared with wild-type PTP-SL (Fig. 4, B and C). Also,
when cells coexpressing wild-type PTP-SL and HA-ERK2
or HA-p38
 
a
 
 were treated with dibutyryl-cAMP, the nu-
clear localization of both MAP kinases was partially re-
stored, and such an effect was prevented by cell preincuba-
tion with H89 (Fig. 4, B and C). However, no effect was
observed upon cell treatment with agents that activate
other kinase pathways, such as EGF or PMA (data not
shown). Furthermore, cotransfection with an inducible ex-
pression vector coding the C
 
a
 
 catalytic subunit of PKA
(cPKA
 
a
 
), also favored the nuclear localization of these
MAP kinases in the presence of PTP-SL (Fig. 4, B and C).
Remarkably, the effect of PKA activation on the colocal-
ization of HA-ERK2 and HA-p38
 
a
 
 with wild-type PTP-
SL was not observed with the PTP-SL S231A mutant (Fig.
4, B and C), demonstrating that phosphorylation of the
Ser
 
231
 
 residue of PTP-SL by PKA inhibits the in vivo asso-
ciation of PTP-SL with HA-ERK2 and HA-p38
 
a
 
, and fa-
vors the nuclear translocation of these kinases.
Figure 3. Transmembrane PTP-
SL retains ERK2 and p38a
outside of the nucleus. COS-7
cells were cotransfected with
pcDNA3-HA-ERK2 or pECE-
HA-p38MAPK, plus pRK5-
PTP-SL 1-549 wild type or
DKIM (D224-239) mutant, as in-
dicated. 48 h after transfection,
cells were costained and ana-
lyzed by immunofluorescence.
HA-ERK2 and HA-p38a were
stained with the mouse anti–HA
mAb 12CA5 plus rhodamine-
conjugated goat anti–mouse an-
tibody (red, A, D, G, and J).
PTP-SL was stained with rabbit
polyclonal anti–PTP-SL anti-
body plus fluorescein isothiocy-
anate–conjugated goat anti–rab-
bit antibody (green, B, E, H, and
K; subcellular localization of
PTP-SL 1-549 corresponds to
perinuclear areas in the cyto-
plasm). In C, F, I, and L, double
color staining is shown; yellow
areas correspond to colocaliza-
tion of HA-ERK2 or HA-p38a,
and PTP-SL. 
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Discussion
 
PKA modulates the activity of MAP kinases in a cell type–
and stimulus-specific manner by interfering with upstream
events from signaling cascades activated through distinct
Ras-like GTPases, including Ras, Rap1, and RalGDS
(Vossler et al., 1997; Miller et al., 1998). In addition, PKA
activity favors the nuclear translocation of ERK1/2 in
PC12 and hippocampal neurons, as well as in presynaptic
sensory neurons from 
 
Aplysia
 
 (Impey et al., 1998; Martin
et al., 1998; Yao et al., 1998). Our results, showing a
crosstalk between the PKA and ERK1/2 and p38
 
a
 
 kinases
through the tyrosine phosphatase PTP-SL, support the ex-
istence of a novel mechanism by which PKA can regulate
the activity of the MAP kinases and their translocation to
the nucleus (Fig. 5). Such a mechanism would involve the
existence, in certain cell types, of a pool of inactive MAP
kinases outside of the nucleus, which would be complexed
with PTP-SL or other KIM-containing PTPs, including
STEP and HePTP (see below). The dissociation equilib-
rium of the complex would depend upon the cell type– and
the stimulus-specific conditions of PKA activity, and the
lack of association would be favored by the PKA-medi-
ated phosphorylation of the KIM regulatory residue on
the PTP. Thus, upon conditions of PKA activation, both
the tyrosine phosphorylation and the entry into the nu-
cleus of the MAP kinases would be prevalent. It should be
noted that the expression of PTP-SL and related isoforms
is restricted to specialized areas of the brain, including the
Purkinje cells in the postnatal cerebellum (Watanabe et
al., 1998; van den Maagdenberg et al., 1999), suggesting
the possibility of a differential regulation of MAP kinase
functions by PTP-SL and PKA during brain development.
The mutational analysis of the KIM of PTP-SL has re-
vealed that the residues involved in the PKA phosphoryla-
tion consensus sequence are also crucial for the docking of
this phosphatase with ERK1/2 (Zúñiga et al., 1999). Such
residues are conserved between the related tyrosine phos-
phatases PTP-SL, STEP, and HePTP, which have been
found to associate with MAP kinases and regulate their
activation (Pulido et al., 1998; Oh-hora et al., 1999; Saxena
et al., 1999a). In this regard, while writing this manuscript,
Saxena et al. (1999b) have reported the negative role of
PKA phosphorylation of the KIM of HePTP in the physi-
cal and functional association of HePTP with MAP ki-
nases. Also, a tyrosine phosphatase from 
 
Drosophila
 
,
PTP-ER, has been found that inactivates MAP kinase, and
that contains three KIMs with consensus phosphorylation
sites for PKA (Karim and Rubin, 1999). Finally, we have
Figure 4. (A) PTP-SL retains HA-ERK2 in the cytoplasm inde-
pendently of its PTP domain. COS-7 cells were cotransfected
with pcDNA3-HA-ERK2 plus pRK5 (mock), or plus pRK5 PTP-
SL 147-549, 1-549, or 1-288 wild type or mutants, as indicated.
Cells were costained and analyzed by immunofluorescence as in
Fig. 3. PTP-SL 147-549 is located in the cytoplasm. Subcellular lo-
calization of PTP-SL 1-549 and 1-288 is identical (see Fig. 3). (B,
C) Effect of PKA on the nuclear localization of HA-ERK2 and
HA-p38a in the presence of PTP-SL. COS-7 cells were cotrans-
fected with pcDNA3-HA-ERK2 (B) or pECE-HA-p38MAPK
(C) plus pRK5-PTP-SL 1-549 wild type or mutants, as indicated.
Similar results were obtained with the double mutant C480S/
S231A and the single mutant S231A (not shown). In some points,
cells were additionally transfected with pCaEV (cPKAa) (1),
and were induced as described in Materials and Methods. Cells
were left untreated (2) or were treated (1) with dibutyryl-
cAMP or dibutyryl-cAMP plus H89, as indicated, and then were
costained and analyzed by immunofluorescence. HA-ERK2 or
HA-p38a nuclear localization is presented as the percentage of
cells coexpressing PTP-SL and HA-ERK2, or PTP-SL and HA-
p38a that showed the MAP kinase located into the nucleus. For
each point, at least 100 double positive cells were scored. Bars
represent the mean 6 SD of at least two separate experiments.
Figure 5. Model of MAP kinase regulation by PKA and PTP-SL.
Pools of MAP kinases are maintained in the cytoplasm and into
the nucleus by the balance between activation stimuli and the
PTP-SL (or other KIM-containing PTPs) inhibitory effects.
Upon PKA activation, the association of PTP-SL with the MAP
kinase is impaired, and MAP kinase tyrosine phosphorylation
and nuclear translocation is favored. The putative regulatory role
for serine/threonine phosphatases (PP) in the dephosphorylation
of PTP-SL, is indicated (see details in the text).The Journal of Cell Biology, Volume 147, 1999 1134
found that the retention of ERK2 outside of the nucleus is
efficiently achieved by PTP-SL catalytically inactive mu-
tants, as well as by truncated PTP-SL molecules lacking
the PTP domain, demonstrating that this domain is dis-
pensable in a such process. Thus, PKA-mediated KIM
phosphorylations could have diverse regulatory effects on
MAP kinase functions, depending on the functional prop-
erties of the affected KIM-containing molecule.
The involvement of distinct kinases in the in vivo phos-
phorylation of PTP-SL is likely to exist, which ultimately
could control the biological functions of this PTP. Thus,
the Thr253 residue of PTP-SL is phosphorylated in vivo by
ERK1/2 upon EGF cell treatment in a manner dependent
of docking through the KIM (Pulido et al., 1998). Further-
more, the Thr253 residue is also a putative PKC phosphory-
lation site, and PTP-SL is phosphorylated in vitro by this
kinase (our unpublished observations). In this context, the
binding of MAP kinases to the KIM of PTP-SL could
mask the PKA phosphorylation motif by steric hindrance,
hampering the phosphorylation of PTP-SL by PKA; con-
versely, phosphorylation of the KIM by PKA difficult the
association of MAP kinases and the subsequent phosphor-
ylation of the Thr253 residue. The results presented here
indicate a major regulatory role on the PTP-SL functions
for the PKA-mediated phosphorylation of the Ser231 resi-
due; accordingly, the basal phosphorylation of PTP-SL in
COS-7 cells is found predominantly in such residue (Fig. 1
B). On the other hand, the functional significance of the
phosphorylation of the Thr253 residue by ERK1/2 remains
elusive. The possibility exists that phosphorylation of
Thr253 regulates the dissociation of PTP-SL from MAP ki-
nases, as it has been suggested for HePTP (Saxena et al.,
1999a). However, the cytoplasmic retention of ERK2 by
PTP-SL was efficiently achieved upon conditions of EGF-
induced phosphorylation of Thr253 (our unpublished ob-
servations). In addition, phosphorylation of this residue
could account for the regulated binding of PTP-SL to
other unidentified molecules. The participation of specific
serine/threonine phosphatases in the in vivo dephosphory-
lation of the Ser231 and Thr253 residues of PTP-SL is also
expected. In this regard, we have found that cell treatment
with okadaic acid induces hyperphosphorylation of the
Ser231 residue, suggesting an active role for PP2A in the in
vivo dephosphorylation of this key residue (Fig. 5). Also,
PP2A and PP2C have been shown to interfere with the ac-
tivation of the MAP kinase pathways by affecting the
phosphorylation of MAP kinases or upstream phosphory-
lation events (Anderson et al., 1990; Chajry et al., 1996;
Takekawa et al., 1998). Thus, a complex network of ki-
nases and phosphatases could be envisioned within the
MAP kinase pathways, which integrate the different sig-
nals to generate specific cell responses. The importance of
the assembly of the molecular components that regulate
the activation of the MAP kinases has been recently out-
lined (Whitmarsh and Davis, 1998; Schaeffer and Weber,
1999). The results reported here point to PKA as a major
regulator of the physical and functional association be-
tween the ERK1/2 and p38a kinases and their inactivating
tyrosine phosphatases.
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